Drug Information

Drug General Information
Drug ID
D0HO2T
Former ID
DCL000479
Drug Name
AZD7325
Drug Type
Small molecular drug
Indication Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42] Phase 2 [522519], [542687]
Company
AstraZeneca
Formula
C19H19FN4O2
InChI
InChI=1S/C19H19FN4O2/c1-3-10-22-19(25)18-16(21)12-7-4-6-11(17(12)23-24-18)15-13(20)8-5-9-14(15)26-2/h4-9H,3,10H2,1-2H3,(H2,21,23)(H,22,25)
InChIKey
KYDURMHFWXCKMW-UHFFFAOYSA-N
PubChem Compound ID
23581869
PubChem Substance ID
46387126, 56006577, 131280825, 141750726, 163367505, 223366045, 223370289, 224103717, 228123802, 241181130, 244246808
Target and Pathway
Target(s) Glutamate receptor AMPA subtype Target Info Agonist [550288]
References
Ref 522519ClinicalTrials.gov (NCT00807937) Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325. U.S. National Institutes of Health.
Ref 542687(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7712).
Ref 550288Clinical pipeline report, company report or official report of AstraZeneca (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.